About Lutris Pharma
Lutris Pharma is a company based in Tel Aviv (Israel) founded in 2016 by Antoni Ribas.. Lutris Pharma has raised $30 million across 1 funding round from investors including Columbus Venture Partners, Pontifax Venture Capital and Peregrine. Lutris Pharma offers products and services including LUT014 and LUT-RD. Lutris Pharma operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Tel Aviv, Israel
- Founders Antoni Ribas
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$30 M (USD)
in 1 rounds
-
Latest Funding Round
$30 M (USD), Series B
Jan 28, 2025
-
Investors
Columbus Venture Partners
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lutris Pharma
Lutris Pharma offers a comprehensive portfolio of products and services, including LUT014 and LUT-RD. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Topical gel that reduces acneiform lesions from EGFR Inhibitors.
Gel treatment for radiation dermatitis in cancer patients.
Funding Insights of Lutris Pharma
Lutris Pharma has successfully raised a total of $30M through 1 strategic funding round. The most recent funding activity was a Series B round of $30 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $30.0M
-
First Round
First Round
(28 Jan 2025)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series B - Lutris Pharma | Valuation | Columbus Venture Partners , Pontifax |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lutris Pharma
Lutris Pharma has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Columbus Venture Partners, Pontifax Venture Capital and Peregrine. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Columbus Venture Partners is focused on biotechnology investment funds.
|
Founded Year | Domain | Location | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Founded Year | Domain | Location | |
|
Peregrine is focused on healthcare innovation through strategic global investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lutris Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Lutris Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lutris Pharma Comparisons
Competitors of Lutris Pharma
Lutris Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lutris Pharma
Frequently Asked Questions about Lutris Pharma
When was Lutris Pharma founded?
Lutris Pharma was founded in 2016 and raised its 1st funding round 9 years after it was founded.
Where is Lutris Pharma located?
Lutris Pharma is headquartered in Tel Aviv, Israel.
Who is the current CEO of Lutris Pharma?
Noa Shelach is the current CEO of Lutris Pharma.
Is Lutris Pharma a funded company?
Lutris Pharma is a funded company, having raised a total of $30M across 1 funding round to date. The company's 1st funding round was a Series B of $30M, raised on Jan 28, 2025.
What does Lutris Pharma do?
Lutris Pharma was founded in 2016 in Tel Aviv, Israel, within the pharmaceutical sector. Focus is placed on developing EGFR inhibitors for anti-cancer treatment, aimed at minimizing dose-limiting dermal toxicity. The proprietary small molecule LUT014, a B-Raf-based inhibitor, is being advanced to reduce acneiform lesions and is currently in phase 1 clinical trials. Operations center on oncology drug innovation.
Who are the top competitors of Lutris Pharma?
Lutris Pharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does Lutris Pharma offer?
Lutris Pharma offers LUT014 and LUT-RD.
Who are Lutris Pharma's investors?
Lutris Pharma has 4 investors. Key investors include Columbus Venture Partners, Pontifax Venture Capital, Peregrine, and aMoon.